In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Guidance programme 2 selected

Guidance programme

Showing 1 to 25 of 25

TitleConsultationTypeConsultation end date
Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer ID6734Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Talazoparib with enzalutamide for treating hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID6460Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy ID6645Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Tislelizumab with platinum-based chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer at high risk of recurrence ID6708Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Draft guidanceTechnology appraisal guidance
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]Draft guidanceTechnology appraisal guidance
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Draft guidanceTechnology appraisal guidance
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]Draft guidanceTechnology appraisal guidance
Nemolizumab for treating prurigo nodularis [ID6451]Final draft guidanceTechnology appraisal guidance
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]Final draft guidanceTechnology appraisal guidance
Elinzanetant for treating moderate to severe vasomotor symptoms associated with menopause ID6359Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Draft guidanceTechnology appraisal guidance
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]Draft guidanceTechnology appraisal guidance
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable ID6736Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Tislelizumab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer with high PD-L1 expression (partial review of TA1058) [GID-TA12513]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Tislelizumab with carboplatin and paclitaxel or nab-paclitaxel for untreated advanced squamous non-small-cell lung cancer (partial review of TA1058) [GID-TA12514]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Mavorixafor for treating WHIM syndrome ID3946Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6625Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Tozorakimab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease [ID6711]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID6463Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]Draft guidanceTechnology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6201Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease ID6733Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia ID6745Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]Draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All